Clinical Trial Data, New Publications, Promotions, Financial Results and FDA Acknowledgements - Research Report on Gilead,

 Clinical Trial Data, New Publications, Promotions, Financial Results and FDA
 Acknowledgements - Research Report on Gilead, Amgen, ACADIA Pharmaceuticals,
                           ViroPharma, and MannKind

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 6, 2013

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Amgen, Inc. (NASDAQ: AMGN), ACADIA
Pharmaceuticals Inc. (NASDAQ: ACAD), ViroPharma Incorporated (NASDAQ: VPHM),
and MannKind Corporation (NASDAQ: MNKD). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Gilead Sciences, Inc. Research Report

On November 2, 2013, Gilead Sciences, Inc. (Gilead) announced results from a
Phase 3 study, PHOTON-1, which evaluated the investigational once-daily
nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus
(HCV) infection among patients co-infected with HIV. According to the results
of the trial, 76% of genotype 1 HCV treatment naïve patients receiving 24
weeks of an all-oral, interferon-free regimen of sofosbuvir plus ribavirin
(RBV) achieved a sustained virologic response 12 weeks after completing
therapy (SVR12). The Company stated that patients who achieve SVR12 are
considered cured of HCV infection. Douglas Dieterich, MD, Professor of
Medicine in the Division of Liver Diseases and Director of Continuing Medical
Education in the Department of Medicine at Mount Sinai School of Medicine
said, "In this study, sofosbuvir-based all-oral therapy achieved high SVR
rates in a hard-to-treat patient population. This regimen may have the
potential to help us overcome the clinical challenge of treating HCV/HIV
co-infection." The Full Research Report on Gilead Sciences, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9898_GILD]

--

Amgen, Inc. Research Report

On October 24, 2013, Amgen, Inc. (Amgen) announced the promotion of two senior
executives, Brian McNamee and Stuart Tross, to the positions of Executive Vice
President and Senior Vice President, respectively, effective as of November 1,
2013. In the new positions, McNamee will be responsible for leading a series
of multi-year initiatives focused on delivering growth and increasing
productivity and agility, while Tross will be responsible for the Company's
global human resources activities. Both, McNamee and Stuart Tross will report
directly to the Company's Chairman and CEO, Robert A. Bradway. The Full
Research Report on Amgen, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

--

ACADIA Pharmaceuticals Inc. Research Report

On October 31, 2013, ACADIA Pharmaceuticals Inc. (ACADIA) announced the
publication of data from its pivotal Phase III -020 Study with pimavanserin in
patients with Parkinson's disease psychosis (PDP) in the November 1, 2013
online issue of The Lancet. The Company informed that in the -020 Study,
pimavanserin demonstrated significant and clinically meaningful benefits and
was safe and well tolerated in patients with PDP. Jeffrey Cummings, M.D.,
Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health and Lead
Author said, "These data indicate that pimavanserin, a selective 5-HT2A
inverse agonist, confers a meaningful clinical benefit in patients with PDP
and has the potential to be an important new treatment option for this
condition for which there is no approved therapy in the U.S." The Full
Research Report on ACADIA Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.analystscorner.com/r/full_research_report/3eb7_ACAD]

--

ViroPharma Incorporated Research Report

On October 31, 2013, ViroPharma Incorporated (ViroPharma) reported Q3 2013
financial results. In Q3 2013, the Company's net sales totaled $113.1 million,
up 24.3% YoY. The Company stated that the increase was primarily driven by
growth in US Cinryze sales. GAAP net income was $4.2 million, or $0.06 per
diluted share during the quarter, compared with a net loss of $4.6 million, or
$0.07 per diluted share, in Q3 2012. "We continue to generate strong growth in
our commercial business, notably led by the acceleration of Cinryze demand
here in the United States. Our pipeline also continues to advance,
establishing a number of important data points over the next several months,"
said Vincent Milano, CEO of ViroPharma. The Full Research Report on ViroPharma
Incorporated - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/c730_VPHM]

--

MannKind Corporation Research Report

On October 30, 2013, MannKind Corporation (MannKind) announced that the FDA
has acknowledged the Company's resubmission of an NDA for AFREZZA Inhalation
Powder. MannKind informed that the FDA considered the updated NDA to be a
complete class 2 response to its Complete Response Letter that was issued in
January 2011 and assigned a user fee goal date of April 15, 2014. The Full
Research Report on MannKind Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/044e_MNKD]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.